Mobocertinib (Exkivity)

Status:

Red

Decision Date:

May 2022

Comments

RED: NICE TA855 - Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy. NHSE commissioned. (Decision date - February 2023)

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again